Intensivmedizin up2date, Table of Contents Intensivmedizin up2date 2017; 13(03): 275-288DOI: 10.1055/s-0043-113362 Allgemeine Intensivmedizin Georg Thieme Verlag KG Stuttgart · New York Prävention von Clostridium-difficile-Infektionen Susanne Kolbe-Busch Recommend Article Abstract Buy Article All articles of this category Nosokomiale Diarrhöen werden hauptsächlich durch Clostridium-difficile-Infektionen in Zusammenhang mit einer Antibiotikatherapie verursacht. Da Infektionen mit diesem Bakterium immer häufiger vorkommen und schwere Verläufe zunehmen, ist es wichtig, sinnvolle Präventionsmaßnahmen umzusetzen. Full Text References Literatur 1 Leffler DA, Lamont JT. Clostridium difficile Infection. Review Article. N Engl J Med 2015; 372: 1539-1548 2 Lessa FC, Mu Y, Bamberg WM. et al. Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015; 372: 825-834 3 Miller MA, Hyland M, Ofner-Agostini M. Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002; 23: 137-140 4 Barbut F, Mastrantonio P, Delmée M. et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007; 13: 1048-1057 5 Zarb P, Coignard B, Griskeviciene J. et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill 2012; 17: pii:20316 6 Hansen S, Sohr D, Piening B. et al. Antibiotic usage in German hospitals: results of the second national prevalence study. J Antimicorb Chemother 2013; 68: 2934-2939 7 Gastmeier P, Kampf G, Wischnewski N. et al. Prevalence of nosocomial infections in representative German hospitals. J Hosp Infect 1998; 38: 37-49 8 Hall IC, OʼToole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe Bacillus difficilis. Am J Dis Child 1935; 49: 390 9 George RH, Symonds JM, Dimock F. et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J 1978; 1: 695 10 Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults. A Systemativ Review. JAMA 2015; 313: 398-408 11 Jangi S, Lamont JT. Asymptomatic colonization by clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 2010; 51: 2-7 12 Kyne L, Warny M, Qamar A. et al. Asymptomatic carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A. N Engl J Med 2000; 342: 390-397 13 See I, Mu Y, Cohen J. et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58: 1394-1400 14 Freeman J, Bauer MP, Baines SD. et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-549 15 Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 881-891 16 Mitchell BG, Dancer SJ, Anderson M. et al. Risk of organism acquisition from prior room occupants: a systematic review and meta-analysis. J Hosp Infect 2015; 91: 211-217 17 Eyre DW, Cule ML, Wilson DJ. et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013; 369: 1195-1205 18 Mermel LA. Diverse sources of C. difficile infection. N Engl J Med 2014; 370: 182-183 19 Evans CT, Safdar N. Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 2015; 60: 66-72 20 Eyre DW, Babakhani F, Griffiths D. et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014; 209: 1446-1451 21 Kuntz JL, Chrischilles EA, Pendergast JF. et al. Incidence of and risk factors for community-associated Clostridium difficile infection: A nested case-control study. BMC Infect Dis 2011; 11: 194 22 Schaumann R, Rodloff A. Clostridium spp. In: Neumeister B, Geiss K, Braun RW. et al., Hrsg. Mikrobiologische Diagnostik. 2. Aufl.. Stuttgart: Thieme; 2009: 546-548 23 Davies KA, Longshaw ChM, Davis GL. et al. Underdiagnosis of Clostridium difficile across Europe: the European multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014; 14: 1208-1219 24 Crobach MJT. et al. European Society of Clinical Microbiology and Infectious Diseases. Update of the diagnostic guidance document for clostridium difficile infection. Clin Microbiol Infect 2016; 22: S63-S81 25 Aguado JM. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect 2015; 90: 117-125 26 Joost I, Speck K, Herrmann M. et al. Characterisation of Clostridium difficile isolates by slpA and tcdC gene sequencing. Int J Antimicrob Agents 2009; 33: 0113-0118 27 Knight DR, Elliott B, Chang BJ. et al. Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev 2015; 28: 721-741 28 He M, Miyajima F, Roberts P. et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45: 109-113 29 Warny M, Pepin J, Fang A. et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084 30 Public Health England. Annual Epidemiological Commentary: Mandatory MRSA, MSSA and E. coli bacteraemia and C. difficile infection data, 2014/2015. Im Internet: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/442952/Annual_Epidemiological_Commentary_FY_2014%20_2015.pdf Stand: 02.02.2016 31 Kuijper EJ, van den Berg RJ, Debast S. et al. Clostridium difficile Ribotype 027, Toxinotype III, the Netherlands. Emerg Infect Dis 2006; 12: 827-830 32 Zaiß NH, Weile J, Ackermann G. et al. A case of Clostridium difficile-associated disease due to the highly virulent clone of Clostridium difficile PCR ribotype 027, March 2007 in Germany. Euro Surveill 2007; 12: pii3306 33 Kleinkauf N, Weiss B, Jansen A. et al. Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill 2007; 12: pii3307 34 Bauer MP, Notermans DW, van Benthem BH. et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73 35 Von Müller L, Mock M, Halfmann A. et al. Epidemiology of Clostridium difficile in Germany based on a single center longterm surveillance and German-wide genotyping of recent isolates provided to the advisory laboratory for diagnostic reasons. Int J Med Microbiol 2015; 305: 807-813 36 Robert Koch-Institut. Clostridium difficile Ratgeber für Ärzte. Stand: 19.5.2016. Im Internet: https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Clostridium.html Stand: 17.08.2017 37 Vonberg RP, Kuijper EJ, Wilcox MH. et al. Infection control measures to limit the spread of Clostridium difficile. CMI 2008; 2-20 38 Martin M, Zingg W, Knoll E. PROHIBIT Study Group. et al. National European guidelines for the prevention of Clostridium difficile infection: a systematic qualitative review. J Hosp Infect 2014; 87: 212-219 39 Dubberke ER, Carling P, Carrico R. et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. SHEA/IDSA Practice Recommendation. ICHE 2014; 35: 628-645 40 Guyatt GH, Oxman AD, Vist GE. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926 41 De With K, Allerberger F, Amann S. et al. S3-Leitlinie: Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus AWMF-Registernummer 092/001. 01.12.2013 Im Internet: http://www.awmf.org/leitlinien/detail/II/092-001.html Stand: 02.02.2016 42 Feazel LM, Malhotra A, Perencevich EN. et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 1748-1754 43 Dubberke ER. Preventing Clostridium difficile infection: Clarifying Common Misperceptions. Medscape 2015. Im Internet: http://www.medscape.com/viewarticle/841721 Stand: 02.02.2016 44 Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen (NRZ). CDAD-KISS Protokoll 2017. Im Internet: http://www.nrz-hygiene.de/fileadmin/nrz/module/cdad/CDAD_Protokoll_2017.pdf Stand: 10.07.2017 45 Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen (NRZ). Web KESS-Portal für KISS. Im Internet: http://www.nrz-hygiene.de/fileadmin/nrz/module/cdad/CDAD_Referenzdaten_2016_DE.pdf ; Stand: 10.07.2017 46 Robert Koch-Institut. Bekanntmachung: Surveillance nosokomialer Infektionen sowie die Erfassung von Krankheitserregern mit speziellen Resistenzen und Multiresistenzen. Bundesgesundheitsbl 2013; 56: 580-583 47 Robert Koch-Institut. Schwer verlaufende Clostridium-difficile-Infektionen: IfSG-Surveillancedaten. Epidemiologisches Bulletin 2014; 27: 233-237 48 Verordnung zur Anpassung der Meldepflichten nach dem Infektionsschutzgesetz an die epidemische Lage (IfSG-Meldepflicht-Anpassungsverordnung – IfSGMeldAnpV) vom 18. März 2016. BGBl. I S. 515.
